Enovis Reports Mixed Q1 2026 Results with 5% Sales Growth
Event summary
- Enovis reported Q1 2026 net sales of $589 million, up 5% year-over-year on a reported basis and 3% organically.
- Reconstructive segment sales grew 11% reported, 6% organic, while Prevention & Recovery was flat reported, 1% organic.
- Adjusted EBITDA was $104 million (17.6% margin), with a net loss of $8 million ($0.15 per share).
- Full-year 2026 guidance reaffirmed: $2.31-2.37 billion revenue (4-6% organic growth), $425-435 million adjusted EBITDA.
- CEO Damien McDonald cited product launches and innovation as growth drivers amid macroeconomic uncertainty.
The big picture
Enovis' Q1 results reflect a medical technology sector grappling with macroeconomic headwinds while betting on innovation-led growth. The 11% Reconstructive surge contrasts with P&R stagnation, highlighting the strategic tension between legacy and high-growth segments. With $2.3 billion in annual revenue, Enovis' ability to navigate geopolitical risks and operationalize acquisitions will determine its trajectory amid industry-wide margin pressures.
What we're watching
- Segment Momentum
- Whether Reconstructive's 11% growth can offset P&R stagnation and drive overall acceleration.
- Integration Challenges
- The pace at which Lima acquisition synergies materialize amid $11 million in Q1 strategic transaction costs.
- Macro Resilience
- How geopolitical tensions and inflation impact Enovis' ability to sustain 4-6% organic revenue growth.
Related topics